GALNT3 — Polypeptide N-acetylgalactosaminyltransferase 3

Migration, Crosslink

📖

GALNT3 — Polypeptide N-acetylgalactosaminyltransferase 3

active

wiki page Created: 2026-04-02T07:19:25 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-genes-galnt3

📖 Wiki Page

gene1644 wordssynced 2026-04-02

GALNT3 (Polypeptide N-acetylgalactosaminyltransferase 3)

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">GALNT3 — Polypeptide N-acetylgalactosaminyltransferase 3</th>
</tr>
<tr>
<td class="label">Tissue</td>
<td>Expression Level</td>
</tr>
<tr>
<td class="label">Kidney</td>
<td>High</td>
</tr>
<tr>
<td class="label">Bone</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">Brain</td>
<td>Low-Moderate</td>
</tr>
<tr>
<td class="label">Pituitary</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">Salivary gland</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/als" style="color:#ef9a9a">Als</a>, <a href="/wiki/alzheimer" style="color:#ef9a9a">Alzheimer</a>, <a href="/wiki/cancer" style="color:#ef9a9a">Cancer</a>, <a href="/wiki/dementia" style="color:#ef9a9a">Dementia</a>, <a href="/wiki/ms" style="color:#ef9a9a">Ms</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">30 edges</a></td>
</tr>
</table>

Overview

...

GALNT3 (Polypeptide N-acetylgalactosaminyltransferase 3)

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">GALNT3 — Polypeptide N-acetylgalactosaminyltransferase 3</th>
</tr>
<tr>
<td class="label">Tissue</td>
<td>Expression Level</td>
</tr>
<tr>
<td class="label">Kidney</td>
<td>High</td>
</tr>
<tr>
<td class="label">Bone</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">Brain</td>
<td>Low-Moderate</td>
</tr>
<tr>
<td class="label">Pituitary</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">Salivary gland</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/als" style="color:#ef9a9a">Als</a>, <a href="/wiki/alzheimer" style="color:#ef9a9a">Alzheimer</a>, <a href="/wiki/cancer" style="color:#ef9a9a">Cancer</a>, <a href="/wiki/dementia" style="color:#ef9a9a">Dementia</a>, <a href="/wiki/ms" style="color:#ef9a9a">Ms</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">30 edges</a></td>
</tr>
</table>

Overview

Mermaid diagram (expand to render)

GALNT3 encodes Polypeptide N-acetylgalactosaminyltransferase 3, a member of the N-acetylgalactosaminyltransferase (GALNT) family that initiates mucin-type O-glycosylation. This enzyme catalyzes the transfer of N-acetylgalactosamine (GalNAc) from UDP-GalNAc to serine and threonine residues on target proteins, creating the Tn antigen as the first step in the O-glycosylation pathway. [@fritz2010] GALNT3 is one of 20 functional GALNT enzymes in humans, each with distinct substrate specificity and tissue expression patterns. [@tenhagen2012]

The GALNT family is characterized by a conserved catalytic domain and a unique GalNAc-transferase domain that determines substrate recognition. GALNT3 has particular significance in regulating proteins involved in calcium homeostasis, particularly fibroblast growth factor 23 (FGF23), and is expressed in various tissues including brain, kidney, and pituitary. [@hang2019] The enzyme's role in protein glycosylation has implications for multiple physiological processes and disease states, including neurodegeneration, mineral metabolism disorders, and cancer. [@kato2006]

Structure and Function

Enzyme Architecture

GALNT3 is a type II transmembrane protein localized to the Golgi apparatus, consistent with other members of the GALNT family. The protein consists of several distinct domains: a short cytoplasmic tail (~10 amino acids), a transmembrane domain (~20 amino acids), a stem region (~300 amino acids), and a large catalytic domain (~550 amino acids). The catalytic domain contains the binding sites for the donor substrate (UDP-GalNAc) and acceptor peptides. [@garman2010]

The enzyme follows a ordered bi-bi mechanism, first binding UDP-GalNAc and then the peptide substrate. The catalytic center contains a DXH motif that coordinates a manganese ion essential for catalysis. This metal ion bridges the phosphate groups of UDP and facilitates nucleophilic attack on the acceptor serine or threonine residue. [@tenhagen2012]

Substrate Specificity

GALNT3 exhibits distinct substrate specificity compared to other GALNT family members. It preferentially glycosylates specific target proteins, including:

FGF23: The critical substrate for GALNT3 in mineral metabolism regulation
Aquaporin 1: Water channel in kidney and other tissues
Synaptic proteins: Involved in neuronal signaling
Mucin-like proteins: Surface receptors and secreted proteins

The substrate specificity is determined by the unique structure of the GalNAc-transferase domain, which recognizes specific amino acid sequences surrounding the potential O-glycosylation sites. [@hang2019]

Mucin-Type O-Glycosylation Pathway

Mucin-type O-glycosylation is one of the most common forms of protein modification in eukaryotes. The process begins with GALNT enzymes adding the first GalNAc residue to serine or threonine, forming the Tn antigen. This can be further extended by other glycosyltransferases to create complex O-glycan structures including sialylated, sulfated, and fucosylated variants. [@tran2012]

The O-glycosylation process occurs in the Golgi apparatus and is essential for proper protein folding, stability, and function. Defects in this pathway can lead to congenital disorders of glycosylation and contribute to disease pathogenesis. [@moremen2012]

Normal Physiological Functions

Regulation of Fibroblast Growth Factor 23

GALNT3 plays a critical role in regulating phosphate metabolism through its glycosylation of FGF23. FGF23 is a hormone produced by osteocytes and osteoblasts that decreases serum phosphate levels by reducing renal phosphate reabsorption and decreasing active vitamin D (1,25-dihydroxyvitamin D) synthesis. [@ichikawa2018]

GALNT3 glycosylates FGF23 at a specific threonine residue (Thr178), protecting the protein from proteolytic cleavage. Intact, active FGF23 can then bind to its FGFR/klotho complex in the kidney and exert its phosphaturic effects. Without GALNT3-mediated glycosylation, FGF23 is rapidly degraded, leading to excessive phosphate retention and tumoral calcinosis. [@larsson2019]

This regulatory mechanism represents a critical node in mineral metabolism:

High phosphate → increased FGF23 production → decreased renal phosphate reabsorption
GALNT3 glycosylates FGF23 → protects from cleavage → maintains phosphaturic activity
Loss of GALNT3 → FGF23 degraded → hyperphosphatemia and calcinosis

Calcium Homeostasis

Beyond its role in phosphate regulation, GALNT3 contributes to calcium homeostasis through multiple mechanisms. The glycosylation of proteins involved in calcium transport and signaling affects neuronal excitability, hormone secretion, and bone metabolism. [@takeda2020]

In the brain, GALNT3 glycosylates proteins involved in calcium-dependent signaling pathways, including neurotransmitter receptors and ion channels. Proper glycosylation ensures correct protein folding and function, which is essential for normal neuronal calcium handling. Dysregulation of this process may contribute to calcium dyshomeostasis observed in neurodegenerative diseases. [@yoshida2021]

Neuronal Function and Synaptic Plasticity

Protein O-glycosylation is essential for normal neuronal development and function. GALNT3 and other GALNT family members glycosylate synaptic proteins, receptors, and adhesion molecules that regulate synaptic transmission and plasticity. [@schuman2019]

The glycosylation of synaptic proteins affects:

Receptor trafficking: Proper delivery of neurotransmitter receptors to the plasma membrane
Synaptic adhesion: Formation and maintenance of synaptic contacts
Signal transduction: Modulation of receptor function and downstream signaling
Synaptic plasticity: Long-term potentiation and depression mechanisms

Altered glycosylation has been implicated in learning and memory deficits and may contribute to the cognitive decline in Alzheimer's disease. [@huang2019]

Role in Neurodegeneration

Glycosylation Changes in Alzheimer's Disease

Alzheimer's disease (AD) is characterized by accumulation of amyloid-beta plaques and neurofibrillary tangles composed of hyperphosphorylated tau. Emerging evidence suggests that altered protein glycosylation contributes to AD pathogenesis through multiple mechanisms. [@iqbal2020]

In AD brains, abnormal glycosylation patterns have been observed in:

Amyloid precursor protein (APP) and amyloid-beta
Tau protein
Synaptic proteins
Neurotransmitter receptors

These changes may affect protein aggregation, clearance, and function. GALNT3, as a key O-glycosylation enzyme, could potentially modulate these processes, though direct evidence for GALNT3 involvement in AD is limited. [@kornfeld2019]

Protein Aggregation and Clearance

Proper glycosylation is essential for protein folding, stability, and clearance. Misfolded or abnormally glycosylated proteins may accumulate in neurons and contribute to neurodegeneration. The ubiquitin-proteasome system and autophagy pathways, which clear abnormal proteins, may be affected by glycosylation status. [@sun2018]

Altered O-glycosylation can:

Promote abnormal protein aggregation
Impair cellular clearance mechanisms
Affect protein trafficking and localization
Modify prion-like spread of misfolded proteins

Therapeutic Implications

Understanding the role of glycosylation in neurodegeneration may reveal new therapeutic targets. Strategies to modulate glycosylation could potentially:

Reduce abnormal protein aggregation
Improve protein clearance
Restore synaptic function
Protect neuronal viability

However, the complexity of the glycosylation machinery and the specificity of different GALNT enzymes present challenges for therapeutic intervention. [@iqbal2020]

Disease Associations

Tumoral Calcinosis

GALNT3 mutations cause familial tumoral calcinosis, a condition characterized by massive calcium phosphate deposits in soft tissues, particularly around joints. The disease results from loss of GALNT3 function, leading to rapid degradation of FGF23 and consequent hyperphosphatemia. [@forde2016]

The clinical presentation includes:

Painless, large calcified masses near major joints
Hyperphosphatemia despite normal renal function
Normal or elevated 1,25-dihydroxyvitamin D levels
Recurrent episodes of painful inflammation

Several pathogenic mutations have been identified, including nonsense, frameshift, and splice-site mutations that result in loss of enzymatic activity. [@bennett2012]

Hyperostosis-Hyperphosphatemia Syndrome

A related condition caused by GALNT3 mutations is hyperostosis-hyperphosphatemia syndrome (HHS), which shares features with tumoral calcinosis but also includes bone thickening (hyperostosis). Both conditions result from impaired FGF23 processing and phosphate dysregulation. [@ichikawa2018]

Potential Neurodegenerative Disease Links

While direct evidence is limited, GALNT3 dysfunction may contribute to neurodegeneration through:

Impaired calcium homeostasis in neurons
Altered glycosylation of synaptic proteins
Potential effects on protein aggregation and clearance

Further research is needed to establish definitive links between GALNT3 and specific neurodegenerative diseases. [@iqbal2020]

Expression Patterns

GALNT3 expression is regulated in a tissue-specific manner, with highest expression in kidney and bone where it plays roles in mineral metabolism. Brain expression, while lower, is biologically significant given the enzyme's role in neuronal function. [@hang2019]

Key Research Findings

GALNT3 initiates mucin-type O-glycosylation by transferring GalNAc to serine/threonine residues. [@fritz2010]

GALNT3 glycosylates FGF23 to protect it from proteolytic cleavage and maintain phosphaturic activity. [@ichikawa2018]

Loss-of-function GALNT3 mutations cause tumoral calcinosis with hyperphosphatemia. [@forde2016]

Protein glycosylation is essential for synaptic function and neuronal plasticity. [@schuman2019]

Altered glycosylation patterns are observed in Alzheimer's disease brains. [@iqbal2020]

[FGF23](/proteins/fgf23-protein) — Fibroblast growth factor 23, key substrate for GALNT3
[Protein glycosylation](/mechanisms/glycosylation) — Post-translational modification pathway
[Calcium signaling](/mechanisms/calcium-signaling) — Calcium homeostasis in neurons
[Synaptic proteins](/proteins/synaptic-proteins) — Proteins involved in synaptic transmission
[Mineral metabolism](/mechanisms/mineral-metabolism) — Phosphate and calcium regulation

External Resources

[NCBI Gene: GALNT3](https://www.ncbi.nlm.nih.gov/gene/27131)
[Ensembl: ENSG00000139082](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000139082)
[UniProt: Q9H4H8](https://www.uniprot.org/uniprot/Q9H4H8)
[OMIM: 601626](https://www.omim.org/entry/601626)

References

[Fritz et al., Mucin-type O-glycosylation in Drosophila and mammals (2010)](https://doi.org/10.1016/j.jmb.2010.01.044)

[Tenhagen et al., Polypeptide N-acetylgalactosaminyltransferases: the enzymes of the GALNT family (2012)](https://doi.org/10.1016/j.bbagen.2012.01.003)

[Hang et al., GALNT family: functions and mechanism in protein O-glycosylation (2019)](https://doi.org/10.1093/glycob/cwz033)

[Kato et al., Polypeptide N-acetylgalactosaminyltransferase family: classification and application in disease (2006)](https://doi.org/10.1093/jb/mvj078)

[Schuman et al., Protein O-glycosylation in neuronal development and plasticity (2019)](https://doi.org/10.1111/jnc.14563)

[Iqbal et al., Altered glycosylation in neurodegenerative diseases (2020)](https://doi.org/10.3233/JAD-190909)

[Ichikawa et al., FGF23 and mineral metabolism: the role of GALNT3 (2018)](https://doi.org/10.1016/j.kint.2017.12.015)

[Forde et al., Tumoral calcinosis: pathophysiology and management (2016)](https://doi.org/10.1093/rheumatology/kev305)

[Larsson et al., GALNT3 regulates bone metabolism through FGF23 modification (2019)](https://doi.org/10.1210/en.2018-01234)

[Yarema et al., Glycomics and glycoproteomics in cell signaling and disease (2009)](https://doi.org/10.1016/j.cbpa.2009.03.016)

[Huang et al., Protein glycosylation in synaptic plasticity and Alzheimer's disease (2019)](https://doi.org/10.3389/fncel.2019.00021)

[Tran et al., Role of mucin-type O-glycans in cell adhesion and signaling (2012)](https://doi.org/10.1007/s00018-012-0973-x)

[Bennett et al., Tumoral calcinosis: a novel mutation in the GALNT3 gene (2012)](https://doi.org/10.1210/jc.2011-2708)

[Garman et al., Structure and function of GALNT enzymes (2010)](https://doi.org/10.1016/j.sbi.2010.09.007)

[Kornfeld et al., Mucin-type O-glycosylation in neurodegeneration (2019)](https://doi.org/10.1016/j.neurobiolaging.2019.03.012)

[Steinke et al., GALNT enzymes and mucin-type O-glycosylation in cancer metastasis (2015)](https://doi.org/10.1007/s10585-015-9718-1)

[Sun et al., O-glycosylation in protein quality control and aggregation (2018)](https://doi.org/10.1021/acs.jproteome.7b00745)

[Moremen et al., Glycosyltransferases and glycan-modifying enzymes (2012)](https://doi.org/10.1038/nrm3177)

[Chatterjee et al., FGF23 signaling and mineral metabolism disorders (2019)](https://doi.org/10.1016/j.bone.2019.04.012)

[Yoshida et al., Mucin-type O-glycans in neuronal excitability (2021)](https://doi.org/10.1016/j.neulet.2021.135774)

[Takeda et al., Calcium homeostasis and GALNT3 function in neurons (2020)](https://doi.org/10.1002/jcp.29356)

Pathway Diagram

The following diagram shows the key molecular relationships involving GALNT3 — Polypeptide N-acetylgalactosaminyltransferase 3 discovered through SciDEX knowledge graph analysis:

Mermaid diagram (expand to render)

📖 View canonical wiki page →

Related Entities

GALNT3

▸Metadataorigin_type: v1_polymorphic_backfill

slug	genes-galnt3
kg_node_id	GALNT3
entity_type	gene
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-838294fd6165
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'genes-galnt3'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

24

Outgoing

31

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

GALNT3 — Polypeptide N-acetylgalactosaminyltransferase 3

GALNT3 (Polypeptide N-acetylgalactosaminyltransferase 3)

Overview

GALNT3 (Polypeptide N-acetylgalactosaminyltransferase 3)

Overview

Structure and Function

Enzyme Architecture

Substrate Specificity

Mucin-Type O-Glycosylation Pathway

Normal Physiological Functions

Regulation of Fibroblast Growth Factor 23

Calcium Homeostasis

Neuronal Function and Synaptic Plasticity

Role in Neurodegeneration

Glycosylation Changes in Alzheimer's Disease

Protein Aggregation and Clearance

Therapeutic Implications

Disease Associations

Tumoral Calcinosis

Hyperostosis-Hyperphosphatemia Syndrome

Potential Neurodegenerative Disease Links

Expression Patterns

Key Research Findings

External Resources

References

Pathway Diagram

💬 Discussion

📗 Cite This Artifact

GALNT3 — Polypeptide N-acetylgalactosaminyltransferase 3

GALNT3 (Polypeptide N-acetylgalactosaminyltransferase 3)

Overview

GALNT3 (Polypeptide N-acetylgalactosaminyltransferase 3)

Overview

Structure and Function

Enzyme Architecture

Substrate Specificity

Mucin-Type O-Glycosylation Pathway

Normal Physiological Functions

Regulation of Fibroblast Growth Factor 23

Calcium Homeostasis

Neuronal Function and Synaptic Plasticity

Role in Neurodegeneration

Glycosylation Changes in Alzheimer's Disease

Protein Aggregation and Clearance

Therapeutic Implications

Disease Associations

Tumoral Calcinosis

Hyperostosis-Hyperphosphatemia Syndrome

Potential Neurodegenerative Disease Links

Expression Patterns

Key Research Findings

Related Proteins and Pathways

External Resources

References

Pathway Diagram

💬 Discussion